Comparison of the efficacy and safety of ultrasonic cycloplasty vs valve implantation and anti-VEGF for the treatment of fundus disease-related neovascular glaucoma

·AIM: To compare the clinical efficacy and safety of ultrasonic cycloplasty(UCP) vs Ahmed glaucoma drainage valve implantation(ADV) in addition to intravitreal antivascular endothelial growth factor(VEGF) for treatment of fundus disease-related neovascular glaucoma(NVG).·METHODS: A total of 43 patients(45 eyes) with NVG secondary to fundus diseases underwent anti-VEGF combined with UCP or ADV from August 2020 to March 2022 were enrolled in this retrospective cohort study. Of them, 14 patients(15 eyes) were treated with both UCP and anti-VEGF as the UCP group and 29 patients(30 eyes) treated with both ADV and anti-VEGF as the ADV group. The success of the treatment was defined as intraocular pressure(IOP) between 11-20 mm Hg with or without using IOP-lowering drugs. IOP measurement, IOP lowering drugs at baseline and follow-ups period and complications were recorded.·RESULTS: The average age was 63.03±9.95 and 52.27±12.89y in ADV and UCP groups, respectively(P=1.947). The fundus pathology included proliferative diabetic retinopathy in 42 eyes and retinal vein occlusion in 3 eyes. All eyes in both groups achieved successful treatment at 3mo. While the success rate was 90.0%(27/30) in the ADV group and 86.7%(13/15) in the UCP group at the last follow-up of 6mo(P>0.05). IOP was significantly lower with reduction of drug use than the baseline in both groups(both P<0.05). And the ADV group needed fewer anti-glaucoma drops than the UCP group from 1d to 3mo. The comfort scores of patients in the ADV group were significantly lower than those in the UCP group in the first week after the operation(P<0.05).·CONCLUSION: UCP is an alternative to the ADV with the same efficacy but non-invasive for the treatment of NVG.

Ahmed valve implantation for neovascular glaucoma after 23-gauge vitrectomy in eyes with proliferative diabetic retinopathy

·AIM: To report on the outcome of Ahmed glaucoma valve (AGV) implantation for the management of neovascular glaucoma (NVG) after 23 -gauge vitrectomy for proliferative diabetic retinopathy (PDR). ·METHODS: Twelve medically uncontrolled NVG with earlier 23 -gauge vitrectomy for PDR underwent AGV implantation. The control of intraocular pressure (IOP), preoperative and postoperative best -corrected visual acuity, the development of intraoperative and postoperative complications were evaluated during the follow-up. ·RESULTS: The mean follow-up was 15.4±4.3 months (9-23 months). Mean preoperative IOP was 49.4±5.1mmHg and mean postoperative IOP at the last visit was 17.5 ± 1.6mmHg. The control of IOP was achieved at the final follow -up visits in all patients, however, 8 of 12 patients still needed anti-glaucoma medication (mean number of medications, 0.8±0.7). The visual acuity improved in nine eyes, and the visual acuity unchanged in three eyes at the final follow -up visits. The complications that occurred were minor hyphema in three eyes, choroid detachment in two eyes, and the minor hyphema and choroid detachments were reabsorbed without any surgical intervention. ·CONCLUSION: AGV implantation is a safe and effective procedure that enables successful IOP control and vision preservation in the NVG patients with the history of earlier 23-gauge vitrectomy for PDR.·

Trabeculectomy with Ex-PRESS implant versus Ahmed glaucoma valve implantation-a comparative study

AIM：To compare the surgical outcomes of trabeculectomy with Ex-PRESS implant and Ahmed glaucoma valve（AGV） implantation. METHODS： Patients who underwent trabeculectomy with Ex-PRESS implants or AGV implantation separately were included in this retrospective chart review.Main outcome measures were surgical failure and complications.Failure was defined as intraocular pressure（IOP） 〉21 mm Hg or 〈5 mm Hg on two consecutive visits after 3mo,reoperation for glaucoma,or loss of light perception.Eyes that had not failed were considered as complete success if they did not required supplemental medical therapy.RESULTS： A total of 64 eyes from 57 patients were included： 31 eyes in the Ex-PRESS group and 33 eyes in the AGV group.The mean follow-up time was 2.6 ±1.1y and 3.3±1.6y,respectively.Patients in the AGV group had significantly higher baseline mean IOP（P =0.005）,lower baseline mean visual acuity（VA）（P =0.02）,and higher proportion of patients with history of previous trabeculectomy（P 〈0.0001）.Crude failure rates were 16.1%,n =5/31 in the Ex-PRESS group and 24.2%,n =8/33 in the AGV group.The cumulative proportion of failure was similar between the groups,P =0.696.The proportion of eyes that experienced postoperative complications was32.3% in the Ex-PRESS group and 60.1% in the AGV group（P =0.0229）.CONCLUSION： Trabeculectomy with Ex-PRESS implant and AGV implantation had comparable failure rates.The AGV group had more post-operative complications,but also included more complex cases with higher baselinemean IOP,worse baseline mean VA,and more previous glaucoma surgeries.Therefore,the results are limited to the cohort included in this study.

Efficacy and safety of intravitreal ranibizumab with panretinal photocoagulation followed by trabeculectomy compared with Ahmed glaucoma valve implantation in neovascular glaucoma

AIM：To evaluate the efficacy and safety of intravitreal ranibizumab（IVR）with panretinal photocoagulation（PRP）followed by trabeculectomy compared with Ahmed glaucoma valve（AGV）implantation in neovascular glaucoma（NVG）.METHODS：This was a retrospective comparative study.We reviewed the cases of a total of 45 eyes from 45 NVG patients among which 23 eyes underwent AGV implantation and the other 22 underwent trabeculectomy. The causes of neovascular glaucoma included：diabetic retinopathy（25 eyes）,and retinal vein occlusion（20 eyes）.All patients received preoperative IVR combined with postoperative PRP. The mean best-corrected visual acuities（BCVA）were converted to the logarithms of the minimum angle of resolution（log MAR）for the statisitical analyses.Intraocular pressure（IOP）,the log MAR BCVA and surgical complications were evaluated before and after surgery.The follow-up period was 12 mo.RESULTS：A total of 39 cases showed complete regression of iris neovascularization at 7d after injection,and 6 cases showed a small amount of residual iris neovascularization. The success rates were 81.8% and 82.6% at 12 mo after trabeculectomy and AGV implantation,respectively. In the trabeculectomy group,the log MAR BCVA improved at the last follow-up in 14 eyes,remained stable in 6 eyes and decreased in 2 eyes. In 4 cases,slight hyphemas developed after trabeculectomy. A shallow anterior chamber developed in 2 cases and 2 vitreous hemorrhages. In the AGV group,the log MAR BCVA improved in 14 eyes,remained stable in 5 eyes and decreased in 4 eyes. Slight hyphemas developed in 3 cases,and a shallow anterior chamber in 3 cases. The mean postoperative IOP was significantly lower in both groups after surgery（F=545.468,P〈0.05）,and the mean postoperative log MAR BCVA was also significantly improved（F=10.964,P〈0.05）with no significant difference between two groups.CONCLUSION：It is safe and effective to treat NVG with this combined procedure,and we found similar results after IVR＋AGV implantation＋PRP and IVR＋trabeculectomy＋PRP in eyes with NVG.

Outcomes of Ahmed valve surgery for refractory glaucoma in Dhahran, Saudi Arabia

AIM: To evaluate the outcomes of Ahmed glaucoma valve(AGV) implantation surgery for refractory glaucoma.METHODS: This one-armed historical cohort study was conducted in 2011. Refractory glaucoma was defined as eyes with an intraocular pressure(IOP) greater than21 mm Hg with maximally tolerated glaucoma medications, failed surgeries, or both. For all eyes with refractory glaucoma that underwent AGV implantation,data were collected on IOP, the best corrected visual acuity(BCVA) and glaucoma medications preoperatively and 4, 6, 12, 24 and 56 wk postoperatively. Logarithm values of IOP were calculated and compared. RESULTS: The study group was comprised of 30patients(30 eyes, 16 males and 14 females) with refractory glaucoma. Mean preoperative IOP was 39.3 ±13.8 mm Hg. Postoperative mean IOP was 15.7±7.1 mm Hg,19.6 ±12.8 mm Hg and 13.9 ±14.2 mm Hg at 12, 24 and56 wk respectively. BCVA was ≥6/60 in 11 eyes preoperatively, and five eyes had BCVA ≥6/60 at 56 wk postoperatively. Preoperatively, more than four medications were used to treat glaucoma in 21 eyes. At12 wk postoperatively, no medications were required to control IOP in 20 eyes. At 56 wk postoperatively, at least one medication was required to control IOP in 10 eyes.Over the entire follow up period, four eyes were treated with yttrium aluminium garnet(YAG) laser and 14 eyes required a second surgery. The AGV was removed in four eyes.CONCLUSION: AGV implantation reduced IOP and the number of medications required to control refractory glaucoma. However, there was a higher risk of decreased vision. Long-term follow up and prompt intervention are recommended.

Severe prelenticular membrane formation on the surface of a hydrophilic acrylic intraocular lens after cataract surgery in an eye with an Ahmed valve implant

【正】Dear Sir,Iam Yong-Sun Ahn,from the Department of Ophthalmology of St.Vincent Hospital of Suwon,Kyungki-do,South Korea.Cataracts are a common problem in eyes with a glaucoma drainage device(GDD),because tube shunt surgery increases the incidence and progression of cataracts[1].An Ahmed valve,the most commonly inserted GDD,is composed of a silicone tube connected to a flat plate sewn to the sclera,and aqueous humor flows from the

Ahmed青光眼阀植入术联合雷珠单抗治疗NVG患者的效果

目的:探讨Ahmed青光眼阀(AGV)植入术联合雷珠单抗治疗新生血管性青光眼(NVG)患者的效果。方法:选择2016年9月—2022年9月河池市第三人民医院收治的66例NVG患者作为研究对象,按照计算机分组法分为两组,各33例。对照组给予AGV植入术治疗,观察组在对照组基础上加用雷珠单抗治疗。比较两组临床疗效、眼压及视力的变化情况、眼动脉血流动力学及并发症发生率。结果:观察组总有效率为93.94%,高于对照组的75.76%,差异有统计学意义(P<0.05)。治疗1周、1个月、3个月后,观察组眼压水平低于对照组,术眼最佳矫正视力(BCVA)高于对照组,差异有统计学意义(P<0.05)。治疗3个月后,观察组舒张末期流速(EDV)、收缩期峰值流速(PSV)高于对照组,血流阻力指数(RI)低于对照组,差异有统计学意义(P<0.05)。两组并发症总发生率比较,差异无统计学意义(P>0.05)。结论:AGV植入术联合雷珠单抗具有良好的临床疗效,可有效改善NVG患者眼动脉血流动力学指标,促进眼部血液循环,以降低眼压,提高视力,且不增加并发症发生率。

抗VEGF联合Ahmed引流阀植入治疗新生血管性青光眼的临床疗效

目的:观察玻璃体腔抗血管内皮生长因子(VEGF)注射联合Ahmed青光眼引流阀(AGV)植入对新生血管性青光眼(NVG)的疗效与安全性。方法:回顾性分析NVG病人47例(47眼)临床资料,其中25例(25眼)实施AGV植入术(AGV组),22例(22眼)行小梁切除术(小梁组)。2组病人术前均予以玻璃体腔内抗VEGF药物注射,术后完成全视网膜光凝,1年内定期随访。比较2组术后最佳矫正视力改善情况和手术前后眼内压(IOP)、抗青光眼药物使用情况及术后并发症、手术成功率。结果:抗VEGF治疗后,2组病人均获得不同程度的虹膜面新生血管消退,且IOP均较术前降低(P<0.05);术后各时点,2组IOP均较术前和抗VEGF治疗后降低(P<0.05)。2组病人间比较,各时间点IOP差异均无统计学意义(P>0.05)。2组术后最佳矫正视力改变情况差异无统计学意义(P>0.05)。2组术后应用抗青光眼药物种类均较术前明显减少(P<0.01)。2组术后并发症发生率差异无统计学意义(P>0.05)。AGV组手术成功率高于小梁组(P<0.05)。结论:抗VEGF药物玻璃体腔内注射联合AGV植入术治疗NVG安全有效。

Ahmed青光眼引流阀睫状沟植入治疗人工晶状体眼青光眼

目的:评价Ahmed青光眼引流阀睫状沟植入术治疗人工晶状体眼青光眼的疗效。方法:采用回顾性病例系列研究。收集2020-02/2022-02柳州市红十字会医院收治的人工晶状体眼青光眼患者18例18眼的临床资料,所有患者均行Ahmed青光眼引流阀睫状沟植入术。观察术前,术后1、3、6、12mo的视力、眼压、角膜内皮细胞密度、角膜内皮细胞丢失率及并发症发生情况。结果:术前平均眼压为43.41±5.33mmHg,术后1、3、6、12mo的平均眼压分别为12.11±3.26、13.82±4.12、13.54±3.83、15.80±4.35mmHg,术后各随访点平均眼压较术前明显下降(F=203.40,P<0.01)。术后各时间点角膜内皮细胞密度较术前降低(F=6.18,P<0.01),但术后1、3、6、12mo各时间点角膜内皮细胞密度及丢失率均无差异(P>0.05),总手术成功率为83%。结论:青光眼引流阀睫状沟植入术治疗人工晶状体眼青光眼安全有效,对角膜内皮细胞损伤小,术后角膜内皮细胞不随时间的变化减少。

对比分析Ahmed青光眼阀植入术与复合式小梁切除术分别联合阿柏西普对新生血管性青光眼患者疗效及视力的影响

目的对比分析Ahmed青光眼阀植入术与复合式小梁切除术分别联合阿柏西普对新生血管性青光眼患者疗效及视力的影响。方法前瞻性选择自2019年1月至2022年12月咸阳市第一人民医院接诊的80例(80眼)新生血管性青光眼患者作为研究对象,按照随机数字表法分为A组和B组,各40例(40眼)。其中A组予以Ahmed青光眼阀植入术治疗,B组予以复合式小梁切除术治疗,两组均联合阿柏西普治疗。记录两组患者不同时间点(手术前、手术后7 d、14 d、1个月、3个月)的眼压、最佳矫正视力,比较两组视力改善效果、并发症发生情况、手术成功率。结果手术后7 d、14 d、1个月、3个月,两组眼压均较手术前明显降低,其中A组手术后1、3个月的眼压分别为(1.92±0.37)、(1.93±0.35)kPa,均明显低于B组[(2.33±0.51)、(2.27±0.42)kPa],差异均有统计学意义(P<0.05)。手术后7 d、14 d、1个月、3个月,两组最佳矫正视力均较手术前提高,差异均有统计学意义(P<0.05);但组间各时间点的最佳矫正视力比较,差异均无统计学意义(P>0.05)。两组手术后3个月的视力改善效果比较,差异无统计学意义(P>0.05)。两组并发症发生率、手术成功率比较,差异均无统计学意义(P>0.05)。结论Ahmed青光眼阀植入术与复合式小梁切除术分别联合阿柏西普治疗新生血管性青光眼的效果显著,安全性均较好,而前者在降低和维持眼压上具有明显优势。

HMGB1在类青光眼引流阀植入术后瘢痕化中的作用机制

目的:探究高迁移率族蛋白1(HMGB1)在类青光眼引流阀植入术后瘢痕组织中的动态表达,揭示HMGB1在青光眼术后瘢痕化中的作用及其可能的作用机制。方法:将60只新西兰大白兔随机分为空白对照组(n=20)、模型组(n=20,结膜囊下硅胶植入)、模型给药组(n=20,硅胶植入联合5-氟尿嘧啶注射)。分别于术后4、8 wk取球结膜组织,采用HE染色和Masson染色检测结膜组织中成纤维细胞和胶原纤维增生及分布情况;免疫组织化学染色检测结膜组织中HMGB1、转化生长因子(TGF)-β1、Smad3、α-平滑肌肌动蛋白(α-SMA)的分布及变化情况;RT-PCR和Western blot检测结膜组织中HMGB1、TGF-β1、Smad3、α-SMA mRNA及蛋白的表达。结果:HE染色和Masson染色结果显示,4、8 wk模型组较空白对照组结膜组织中炎症细胞、成纤维细胞及胶原纤维增生明显,而4、8 wk模型给药组结膜组织中成纤维细胞及胶原纤维增生相对于同时期模型组明显减少。免疫组织化学染色结果显示,4、8 wk模型组结膜组织中可见HMGB1、TGF-β1、Smad3、α-SMA蛋白表达,呈棕褐色染色,8 wk模型组染色更深,而4、8 wk模型给药组较同时期模型组阳性染色程度下降。4、8 wk模型组结膜组织中HE染色成纤维细胞数与免疫组织化学染色HMGB1的表达水平均呈正相关(r=0.602、0.703,均P<0.05)。RT-PCR和Western blot结果显示,4、8 wk模型组结膜组织中HMGB1、TGF-β1、Smad3、α-SMA mRNA及蛋白表达量显著高于空白对照组(均P<0.05),4、8 wk模型给药组结膜组织中HMGB1、TGF-β1、Smad3、α-SMA mRNA及蛋白表达量显著低于同时期模型组(均P<0.05)。模型组和模型给药组中HMGB1与TGF-β1、Smad3的mRNA表达水平具有正相关性(均P<0.05)。结论:类青光眼引流阀植入术后随时间延长HMGB1表达升高,HMGB1在青光眼术后具有致瘢痕形成的作用,并可能通过TGF-β/Smad信号通路参与瘢痕化的发生发展。

葡萄膜炎继发性青光眼与其他难治性青光眼Ahmed青光眼引流阀植入后前房反应的非随机对照研究

背景 葡萄膜炎继发性青光眼患者由于葡萄膜的炎症而导致血-房水屏障的破坏,局部手术的创伤刺激可加重炎症反应,对术眼前房炎症反应进行定量检测可监测眼部反应程度. 目的 探讨葡萄膜炎继发性青光眼患者行Ahmed青光眼引流阀植入术后前房内炎症反应是否重于其他类型的难治性青光眼.方法 采用前瞻性非随机对照的病例对照研究方法,于2011年10月至2012年7月纳入在中山大学中山眼科中心确诊的难治性青光眼29例29眼,分为葡萄膜炎继发性青光眼组（10眼）及其他类型的难治性青光眼组（19眼）,2个组间术眼术前性别、年龄、眼压及房水闪辉值等基线特征匹配.所有患者均接受Ahmed房水引流阀植入术并随访3个月,记录术前、术后1d、3d、1周、2周、1个月和3个月术眼的眼压,同时采用FC-2000激光蛋白细胞检测仪定量测定术眼的房水闪辉值,以光粒子数/ms表示.比较2个组间房水引流阀植入术后房水闪辉值的不同,对术眼手术前后眼压值变化与房水闪辉值变化的关系进行分析. 结果 葡萄膜炎继发性青光眼组术后1d、3d和1周房水闪辉值分别为[21.10 （10.50,38.58）]、[88.00（23.55,168.63）]和[29.90（8.90,65.18）]光粒子数/ms,均明显高于术前的[13.53（7.60,24.00）]光粒子数/ms,差异均有统计学意义（均P＜0.01）,术后1个月和3个月房水闪辉值分别为[6.45 （4.70,13.50）]光粒子数/ms和[8.95 （6.23,18.20）]光粒子数/ms,均低于术前值,差异均有统计学意义（均P＜0.01）;其他类型青光眼组遵循同样的趋势.术后3个月葡萄膜炎继发性青光眼组术眼房水闪辉值明显高于其他类型青光眼组,差异有统计学意义（q=-3.445,P＜0.01）.术后2个组间眼压的比较差异无统计学意义（P＞0.05）.所有患者术眼术后眼压值均逐渐下降,术前及术后1d、3d、1周、2周、1个月和3个月术眼眼压与前房闪辉值间均无明显相关性（rs =0.136,P=0.481;rs=0.019,P=0.922;rs =-0.035,P=0.858;r,=0.317,P=0.094;rs=0.034,P=0.861;rs=-0.094,P=0.628;rs=0.065,P=0.738）. 结论 FC-2000激光蛋白细胞检测仪检测证实Ahmed房水引流阀植入术可导致术眼术后早期的前房炎症反应,葡萄膜炎继发性青光眼患者术后炎症反应的恢复较缓慢,术后3个月时房水闪辉值仍高于其他类型的难治性青光眼.

FP-7/FP-8 Ahmed青光眼引流阀植入治疗儿童难治性青光眼的临床评价

背景 临床研究已证实FP-7/FP-8 Ahmed青光眼引流阀治疗成人难治性青光眼有效且安全,但由于儿童青光眼的病理机制复杂及其临床表现的多样性,采用FP-7/FP-8 Ahmed青光眼引流阀治疗儿童难治性青光眼的疗效和安全性评价较少. 目的 评价FP-7/FP-8 Ahmed青光眼引流阀治疗儿童难治性青光眼的临床效果.方法 采用回顾性系列病例观察研究设计,纳入2008年10月至2011年4月于沧州市中心医院行FP-7/FP-8 Ahmed青光眼引流阀植入术的儿童青光眼患者26例30眼,患者年龄为4个月～16.5岁,包括先天性青光眼小梁/房角切开术后高眼压、晚期先天性青光眼、无晶状体眼或人工晶状体植入术后青光眼、外伤性青光眼和Sturge-Weber综合征.分别于术后1周及1、6、12、24个月复查,观察术眼术后眼压、手术并发症及手术成功率. 结果 患者术前平均眼压为（36.93±177;10.56） mmHg（1 mmHg=0.133 kPa）,术后1周及1、6、12、24个月眼压分别为（13.13±177;3.34）、（14.13±177;3.15）、（15.93±177;4.76）、（17.96±177;5.37）、（19.74±177;5.43） mmHg,不同时间点的眼压整体比较差异有统计学意义（F=58.929,P＜0.05）;与术前眼压值比较,术后1周及1、6、12、24个月术眼眼压均明显下降,差异均有统计学意义（t=11.641、11.458、10.688、7.988、8.018,P＜0.05）.本组术眼术后1周及1、6、12、24个月的累积总成功率分别为100％、96.67％、93.21％、85.76％和71.46％.术后共有8眼出现轻度并发症,包括浅前房4眼、引流管阻塞1眼、前房积血2眼和引流管暴露1眼,经药物或手术治疗后痊愈,未发现术后严重并发症.结论 FP-7/FP-8 Ahmed青光眼引流阀植入术治疗儿童难治性青光眼有效且安全,可作为儿童难治性青光眼的首选手术方式之一.

Ahmed青光眼阀治疗难治性青光眼的作用和现状

青光眼是致盲性疾病,难治性青光眼的治疗更为棘手。青光眼房水引流物的出现,是治疗难治性青光眼的突破性进展,提高了中短期治疗成功率,同时也存在较多并发症。本文就常用的引流植入物—Ahmed青光眼阀在治疗难治性青光眼中的作用和研究现状作一综述。

改良的Ahmed青光眼引流阀植入术治疗难治性青光眼的疗效

目的:观察改良的Ahmed引流阀植入术治疗难治性青光眼的临床疗效。方法:回顾性分析2014-01/2018-09在我院行Ahmed引流阀植入手术的难治性青光眼患者30例32眼,按手术方式分为试验组(14例16眼)及对照组(16例16眼)。试验组采用改良Ahmed引流阀植入术,对照组采用传统Ahmed引流阀植入术。观察Ahmed引流阀植入术后1d,1wk,1、3、6mo视力、眼压和并发症等情况。结果:术前,术后1d,1wk,1、3、6mo两组患者眼压无差异(均P>0.05)。术后6mo,两组患者BCVA较术前无差异(均P>0.05)。术后6mo,试验组手术总成功率为87%,对照组为75%(P=0.654),试验组平均住院时间(4.50±1.37d)低于对照组(7.63±3.69d)(P=0.003)。试验组术后6mo内未发生浅前房,对照组术后浅前房发生率为31%。结论:改良Ahmed引流阀植入术治疗难治性青光眼,操作简便,平均住院日短,术后浅前房发生率低,是治疗难治性青光眼的有效方法。

Ahmed青光眼引流阀植入术治疗难治性青光眼的临床疗效观察

[目的]评价Ahm ed青光眼引流阀植入术治疗难治性青光眼的疗效并探讨其并发症的防治。[方法]回顾性分析对23例难治性青光眼行Ahm ed青光眼阀植入术的疗效,主要观察指标为手术前后视力、眼压、并发症及手术成功率等,术后随访6~18月。[结果]术后最佳矫正视力不变8眼,提高12眼,下降3眼。术后眼压控制的有效率达到86.96%,术后并发症主要是早期的短暂性浅前房和高眼压,前房积血,以及晚期的滤过道瘢痕纤维化。[结论]Ahm ed引流阀植入术是治疗难治性青光眼比较有效的方法。

Ahmed青光眼阀植入联合囊袋张力环植入及超声乳化术治疗外伤继发性青光眼合并晶体脱位的疗效观察

目的：观察Ahmed青光眼阀植入联合囊袋张力环植入及超声乳化术治疗外伤继发性青光眼合并晶体脱位的临床疗效。方法：2010年至2014年收治我院25例25眼外伤患者,均表现为继发性青光眼合并晶体不全脱位。予以充分足量的抗炎及降眼压治疗后,眼压不能控制,予以行Ahmed青光眼阀植入联合囊袋张力环植入及白内障超声乳化人工晶体植入术。观察术后患者视力、眼压、抗青光眼药物使用、并发症的发生。结果：所有手术均顺利完成。术后视力由术前0.23±0.11,提高至0.56±0.17。术前眼压（48.44±3.33）mm Hg,术后随访1周,1月、3月、6月、12月、18月眼压分别为（10.16±1.65）mm Hg、（12.56±1.32）mm Hg、（17.84±2.51）mm Hg、（20.08±2.29）mm Hg、（20.28±2.34）mm Hg、（20.60±2.83）mmHg,采用术前术后单因素重复测量方差分析,差异有统计学意义（P〈0.01）。眼压控制有效率84%。术前使用抗青光眼药物3~6种,平均4种,术后0~2种,平均1种。术后并发症有术后浅前房,管口阻塞,引流盘周包裹,均予以对症处理后,前房恢复,眼压控制。结论：眼外伤继发青光眼为难治性青光眼,若合并有晶体不全脱位时治疗难度更大。采用Ahmed青光眼阀植入可以有效控制眼压,同时联合囊袋张力环植入及白内障超声乳化术人工晶体植入,可以最大限度的保存患者的视力。该方法为此类患者的康复提供了一种安全、有效的选择。

XEN引流管植入联合丝裂霉素C治疗开角型青光眼

目的:探讨XEN引流管植入联合丝裂霉素C(MMC)治疗开角型青光眼(OAG)的临床疗效和安全性。方法:回顾性纳入OAG患者37例37眼,按初始接受抗青光眼手术治疗与否分为初次青光眼手术组17例17眼,多次青光眼手术组20例20眼,记录各随访时间点眼压、降眼压药物种类及并发症,术后随访时间大于1 a。结果:术后1 a,初次与多次青光眼手术组眼压分别从术前27.56±9.94、28.43±14.18 mmHg降至15.16±3.65、17.18±5.83 mmHg,分别下降55.01%和60.43%(t=4.863,P<0.001;t=3.255,P=0.004)。术后不同时间点两组眼压均较术前降低,时间有差异(F_(时间)=6.876,P_(时间)<0.001),组间及交互均无差异(F_(组间)=0.242,P_(组间)=0.626;F_(时间×组间)=0.959,P_(时间×组间)=0.458)。两组手术完全成功率分别为47%、45%,条件成功率为76%、75%(Z=-0.115,P=0.909),完全成功与条件成功累积生存率分析均无差异(χ^(2)=0.042,P=0.838;χ^(2)=0.004,P=0.949)。术后1 a随访时两组降眼压药物均由术前的3(2,3)种减少为1(0,2)种(Z=-3.289、-3.796,均P<0.001),组间无差异(Z=-0.581,P=0.561)。术后短期并发症以低眼压为主,前房出血次之,远期并发症以滤过泡包裹为主,除外引流管暴露及脱落各1眼,无其他严重并发症发生。结论:XEN引流管植入联合MMC治疗初次与多次青光眼手术OAG患眼均安全有效,但多次青光眼手术组滤过泡包裹发生率高。

Ahmed青光眼引流阀植入术治疗新生血管性青光眼的新进展

新生血管性青光眼（NVG）是一类以虹膜及房角新生血管形成为特征的继发性青光眼，其致盲率高，治疗棘手，目前主要的治疗策略包括视网膜缺血的治疗、药物控制眼压和手术降低眼压3个方面。虽然NVG有许多手术治疗方法，但多存在并发症，远期效果尚不能令人满意。Ahmed青光眼引流阀植入术（AGVI）因其术后浅前房、低眼压等并发症少，术后眼压控制稳定，是NVG的首选治疗方式之一，影响手术疗效的主要因素为纤维增生、新生血管再次形成等，AGVI联合抗纤维治疗及抗血管内皮生长因子（VEGF）治疗可能为NVG的治疗提供了新的途径。近年来研究表明，AGVI联合抗VEGF药物的应用能够提高手术成功率。AGVI术中联合应用抗纤维药物，如丝裂霉素C、缓释型抗纤维药物等可以改善手术预后。本文针对AGVI治疗NVG及联合抗纤维化、抗VEGF治疗的研究进展进行综述。

Ahmed青光眼阀植入治疗难治性青光眼

目的:探讨Ahmed青光眼阀植入治疗难治性青光眼的临床疗效。方法:回顾性研究我院Ahmed青光眼阀植入术治疗21例21眼难治性青光眼的临床疗效并进行总结分析。结果:术前平均眼压为44.6±7.2mmHg,术后6mo末次随访平均眼压15.4±5.3mmHg;视力提高4眼,无改变14眼,降低3眼;手术并发症主要包括术后前房形成迟缓2眼、持续高眼压1眼、引流管暴露1眼、角膜失代偿1眼、引流盘纤维包裹3眼;手术成功率为86%。结论:Ahmed青光眼阀植入术是治疗难治性青光眼有效和安全的方法。